Animal models of cancer pain

Comparative Medicine

Volumn 58, Issue 3, 2008, Pages 220-233

  Pacharinsak, Cholawat ^a   Beitz, Alvin ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; CISPLATIN; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1; VINCRISTINE;

ALLODYNIA; ANTINOCICEPTION; BONE CANCER; BONE MARROW SUPPRESSION; BONE PAIN; BURNING SENSATION; CANCER INVASION; CANCER MODEL; CANCER PAIN; CONTINUOUS INFUSION; DORSAL ROOT; HUMAN; HYPERALGESIA; HYPERESTHESIA; NEPHROTOXICITY; NERVE FIBER C; NEUROBIOLOGY; NEUROTOXICITY; NOCICEPTION; NONHUMAN; OTOTOXICITY; PAIN ASSESSMENT; PANCREAS CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; REVIEW; SKIN TINGLING; TUMOR XENOGRAFT;

ANIMALS; MODELS, ANIMAL; NEOPLASMS; PAIN; PAIN MEASUREMENT;

EID: 46849095396     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (197)

1. Aley KO, Reichling DB, Levine JD. 1996. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience 73:259-265.
2. Allen JW, Mantyh PW, Horais K, Tozier N, Rogers SD, Ghilardi JR, Cizkova D, Grafe MR, Richter P, Lappi DA, Yaksh TL. 2006. Safety evaluation of intrathecal substance P-saporin, a targeted neurotoxin, in dogs. Toxicol Sci 91:286-298.
3. Andersen C, Bagi CM, Adams SW. 2003. Intratibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats. J Musculoskelet Neuronal Interact 3:148-155.
4. Apfel SC, Upton RB, Arezzo JC, Kessler JA. 1991. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29:87-90.
5. Asai H, Ozaki N, Shinoda M, Nagamine K, Tohnai I, Ueda M, Sugiura Y. 2005. Heat and mechanical hyperalgesia in mice model of cancer pain. Pain 117:19-29.
6. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G, Taylor I.2001. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer 85:1759-1763.
7. Authier N, Coudore F, Eschalier A, Fialip J. 1999. Pain-related behaviour during vincristine-induced neuropathy in rats. Neuroreport 10:965-968.
8. Authier N, Fialip J, Eschalier A, Coudore F. 2000. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci Lett 291:73-76.
9. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. 2000. Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res 887:239-249.
10. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. 2003. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 182:12-20.
11. Baamonde A, Lastra A, Fresno MF, Llames S, Meana A, Hidalgo A, Menendez L. 2004. Implantation of tumoral XC cells induces chronic, endothelin-dependent, thermal hyperalgesia in mice. Cell Mol Neurobiol 24:269-281.
12. Bauerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR. 2005. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115:177-186.
13. Beyreuther BK, Callizot N, Brot MD, Feldman R, Bain SC, Stohr T. 2007. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur J Pharmacol 565:98-104.
14. Blackburn-Munro G. 2004. Pain-like behaviours in animals-how human are they? Trends Pharmacol Sci 25:299-305.
15. Blair JM, Zhou H, Seibel MJ, Dunstan CR. 2006. Mechanisms of disease: roles of OPG, RANKL, and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3:41-49.
16. Blouin S, Basle MF, Chappard D. 2005. Rat models of bone metastases. Clin Exp Metastasis 22:605-614.
17. Boyle FM, Wheeler HR, Shenfield GM. 1999. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 41:107-116.
18. Brigatte P, Sampaio SC, Gutierrez VP, Guerra JL, Sinhorini IL, Curi R, Cury Y. 2007. Walker 256 tumor-bearing rats as a model to study cancer pain. J Pain 8:412-421.
19. Brown DC, Iadarola MJ, Perkowski SZ, Erin H, Shofer F, Laszlo KJ, Olah Z, Mannes AJ. 2005. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology 103:1052-1059.
20. Bruera E, Lawlor P. 1997. Cancer pain management. Acta Anaesthesiol Scand 41:146-153.
21. Cain DM, Wacnik PW, Eikmeier L, Beitz A, Wilcox GL, Simone DA. 2001. Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med 2:15-23.
22. Cavaletti G, Bogliun G, Crespi V, Marzorati L, Zincone A, Marzola M, Rota S, Galli A, Tredici P, Tredici G. 1997. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 15:199-206.
23. Cavaletti G, Tredici G, Braga M, Tazzari S. 1995. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133:64-72.
24. Ceyhan GO, Michalski CW, Demir IE, Muller MW, Friess H. 2008. Pancreatic pain. Best Pract Res Clin Gastroenterol 22:31-44.
25. Cleary JF. 2000. Cancer pain management. Cancer Control 7:120-131.
26. Cleeland CS. 1984. The impact of pain on the patient with cancer. Cancer 54:2635-2641.
27. Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, DiStefano PS. 1998. Physiological characterization of taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 43:46-55.
28. Clohisy DR, Mantyh PW. 2003. Bone cancer pain. Clin Orthop Relat Res 415(Suppl):S279-S288.
29. Clohisy DR, Mantyh PW. 2004. Bone cancer pain and the role of RANKL/OPG. J Musculoskelet Neuronal Interact 4:293-300.
30. Clohisy DR, Ramnaraine ML. 1998. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res 16:660-666.
31. Coleman RE. 2000. Management of bone metastases. Oncologist 5:463-470.
32. Coleman RE. 2001. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176.
33. Coleman RE, Rubens RD. 1987. The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66.
34. Davar G. 2001. Endothelin 1 and metastatic cancer pain. Pain Med 2:24-27.
35. De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J. 1981. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 78:5608-5612.
36. de Koning P, Neijt JP, Jennekens FG, Gispen WH. 1987. ORG2766 protects from cisplatin-induced neurotoxicity in rats. Exp Neurol 97:746-750.
37. Dernell WS, Straw RC, Withrow SJ. 2001. Tumors of the skeletal system. In: Withrow SJ, MacEwen EG, editors. Small animal clinical oncology. Philadelphia: WB Saunders. p 378-417.
38. di Mola FF, di Sebastiano P. 2008. Pain and pain generation in pancreatic cancer. Langenbecks Arch Surg 2008 [Epub].
39. Dina OA, Chen X, Reichling D, Levine JD. 2001. Role of protein kinase cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 108:507-515.
40. Donovan-Rodriguez T, Dickenson AH, Urch CE. 2004. Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain. Neurosci Lett 360:29-32.
41. Donovan-Rodriguez T, Dickenson AH, Urch CE. 2005. Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. Anesthesiology 102:132-140.
42. Donovan-Rodriguez T, Urch CE, Dickenson AH. 2006. Evidence of a role for descending serotonergic facilitation in a rat model of cancer-induced bone pain. Neurosci Lett 393:237-242.
43. Dorsi MJ, Chen L, Murinson BB, Pogatzki-Zahn EM, Meyer RA, Belzberg AJ. 2008. The tibial neuroma transposition (TNT) model of neuroma pain and hyperalgesia. Pain 134:320-334.
44. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. 2007. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage 33:166-179.
45. El Mouedden M, Meert TF. 2005. Evaluation of pain-related behavior, bone destruction, and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain. Pharmacol Biochem Behav 82:109-119.
46. Erin N, Boyer PJ, Bonneau RH, Clawson GA, Welch DR. 2004. Capsaicin-mediated denervation of sensory neurons promotes mammary tumor metastasis to lung and heart. Anticancer Res 24:1003-1009.
47. null mouse dorsal root ganglia. Neurosci Lett 308:1-4.
48. Foley KM. 1996. Controlling the pain of cancer. Sci Am 275:164-165.
49. Foley KM. 1999. Advances in cancer pain. Arch Neurol 56:413-417.
50. Fox A, Medhurst S, Courade JP, Glatt M, Dawson J, Urban L, Bevan S, Gonzalez I. 2004. Antihyperalgesic activity of the COX2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain 107:33-40.
51. Freedman SD, Callery MP. 2007. Central control of pancreatic cancer pain: protecting the enemy? Gastroenterology 132:1191-1192.
52. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. 1998. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78:157-169.
53. Gebhart GF. 1999. Animal models of pain. ILAR J 40.
54. Ghilardi JR, Rohrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, Carruthers NI, Swanson D, Kuskowski M, Flores CM, Julius D, Mantyh PW. 2005. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25:3126-3131.
55. Giraudel JM, Diquelou A, Lees P, Toutain PL. 2005. Development and validation of a new model of inflammation in the cat and selection of surrogate endpoints for testing antiinflammatory drugs. J Vet Pharmacol Ther 28:275-285.
56. Gispen WH, Hamers FP, Vecht CJ, Jennekens FG, Neyt JP. 1992. ACTH/MSH like peptides in the treatment of cisplatin neuropathy. J Steroid Biochem Mol Biol 43:179-183.
57. Goblirsch M, Lynch C, Mathews W, Manivel JC, Mantyh PW, Clohisy DR. 2005. Radiation treatment decreases bone cancer pain through direct effect on tumor cells. Radiat Res 164:400-408.
58. Goblirsch M, Mathews W, Lynch C, Alaei P, Gerbi BJ, Mantyh PW, Clohisy DR. 2004. Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 161:228-234.
59. Goblirsch M, Zwolak P, Ramnaraine ML, Pan W, Lynch C, Alaei P, Clohisy DR. 2006. Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture. Clin Cancer Res 12:3168-3176.
60. Goblirsch MJ, Zwolak P, Clohisy DR. 2005. Advances in understanding bone cancer pain. J Cell Biochem 96:682-688.
61. Goblirsch MJ, Zwolak PP, Clohisy DR. 2006. Biology of bone cancer pain. Clin Cancer Res 12:6231s-6235s.
62. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. 2005. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 5 Suppl:S46-S53.
63. Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW. 2005. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 65:9426-9435.
64. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. 1988. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
65. Hartel M, di Mola FF, Selvaggi F, Mascetta G, Wente MN, Felix K, Giese NA, Hinz U, Di Sebastiano P, Buchler MW, Friess H. 2006. Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut 55:519-528.
66. Hasue F, Kuwaki T, Yamada H, Fukuda Y, Shimoyama M. 2004. Inhibitory actions of endothelin 1 on pain processing. J Cardiovasc Pharmacol 44:S318-S320.
67. Higuera ES, Luo ZD. 2004. A rat pain model of vincristine-induced neuropathy. Methods Mol Med 99:91-98.
68. Honore P. 2006. Behavioral assessment of neuropathic pain in preclinical models. Drug Dev Res 67:302-307.
69. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW. 2000. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521-528.
70. Honore P, Mantyh PW. 2000. Bone cancer pain: from mechanism to model to therapy. Pain Med 1:303-309.
71. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, Mantyh PW. 2000. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98:585-598.
72. Honore P, Schwei J, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW. 2000. Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res 129:389-397.
73. Horwitz SB. 1992. Mechanism of action of taxol. Trends Pharmacol Sci 13:134-136.
74. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
75. Joseph EK, Levine JD. 2003. Sexual dimorphism for protein kinase Cε signaling in a rat model of vincristine-induced painful peripheral neuropathy. Neuroscience 119:831-838.
76. Joshi SK, Honore P. 2006. Animal models of pain for drug discovery. Expert Opin Drug Discov 1:323-334.
77. Jourdan D, Ardid D, Eschalier A. 2001. Automated behavioural analysis in animal pain studies. Pharmacol Res 43:103-110.
78. Karai L, Brown DC, Mannes AJ, Connelly ST, Brown J, Gandal M, Wellisch OM, Neubert JK, Olah Z, Iadarola MJ. 2004. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J Clin Invest 113:1344-1352.
79. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, Simone DA. 2003. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103:175-186.
80. Khasabov SG, Ghilardi JR, Mantyh PW, Simone DA. 2005. Spinal neurons that express NK1 receptors modulate descending controls that project through the dorsolateral funiculus. J Neurophysiol 93:998-1006.
81. Khasabov SG, Hamamoto DT, Harding-Rose C, Simone DA. 2007. Tumor-evoked hyperalgesia and sensitization of nociceptive dorsal horn neurons in a murine model of cancer pain. Brain Res 1180:7-19.
82. King T, Vardanyan A, Majuta L, Melemedjian O, Nagle R, Cress AE, Vanderah TW, Lai J, Porreca F. 2007. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain 132:154-168.
83. Kohler DR, Goldspiel BR. 1994. Paclitaxel (taxol). Pharmacotherapy 14:3-34.
84. KuKanich B, Lascelles BD, Papich MG. 2005. Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs. J Vet Pharmacol Ther 28:371-376.
85. Kumar N. 1981. Taxol-induced polymerization of purified tubulin mechanism of action. J Biol Chem 256:10435-10441.
86. Kurbel S, Kurbel B, Kovacic D, Sulava D, Krajina Z, Dmitrovic B, Sokcevic M. 1999. Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors. Med Hypotheses 52:329-333.
87. Lacroix-Fralish ML, Ledoux JB, Mogil JS. 2007. The pain genes database: an interactive web browser of pain-related transgenic knockout studies. Pain 131:3.el-3.e4.
88. Lariviere WR, Wilson SG, Laughlin TM, Kokayeff A, West EE, Adhikari SM, Wan Y, Mogil JS. 2002. Heritability of nociception. III. Genetic relationships among commonly used assays of nociception and hypersensitivity. Pain 97:75-86.
89. Lee BH, Seong J, Kim UJ, Won R, Kim J. 2005. Behavioral characteristics of a mouse model of cancer pain. Yonsei Med J 46:252-259.
90. Lees P, Landoni MF, Giraudel J, Toutain PL. 2004. Pharmacodynamics and pharmacokinetics of nonsteroidal antiinflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther 27:479-490.
91. Lesage P, Portenoy RK. 1999. Trends in cancer pain management. Cancer Control 6:136-145.
92. Levy MH. 1996. Pharmacologic treatment of cancer pain. N Engl J Med 335:1124-1132.
93. Liepe K, Geidel H, Haase M, Hakenberg OW, Runge R, Kotzerke J. 2005. New model for the induction of osteoblastic bone metastases in rat. Anticancer Res 25:1067-1073.
94. Liepe K, Runge R, Kotzerke J. 2005. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 131:60-66.
95. Lin CS, Tsaur ML, Chen CC, Wang TY, Lin CF, Lai YL, Hsu TC, Pan YY, Yang CH, Cheng JK. 2007. Chronic intrathecal infusion of minocycline prevents the development of spinal-nerve ligation-induced pain in rats. Reg Anesth Pain Med 32:209-216.
96. Lindsay TH, Jonas BM, Sevcik MA, Kubota K, Halvorson KG, Ghilardi JR, Kuskowski MA, Stelow EB, Mukherjee P, Gendler SJ, Wong GY, Mantyh PW. 2005. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight, and disease progression. Pain 119:233-246.
97. Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW. 2001. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61:4038-4047.
98. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW. 2002. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer versus inflammatory pain. Pain 99:397-406.
99. Lynch JJ 3rd, Wade CL, Zhong CM, Mikusa JP, Honore P. 2004. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 110:56-63.
100. Ma C. 2007. Animal models of pain. Int Anesthesiol Clin 45:121-131.
101. Mantyh PW. 2004. A mechanism-based understanding of bone cancer pain. Novartis Found Symp 261:194-214;
102. discussion 214-219, 256-261.
103. Mantyh PW. 2006. Cancer pain and its impact on diagnosis, survival, and quality of life. Nat Rev Neurosci 7:797-809.
104. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. 2002. Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201-209.
105. Mantyh PW, Hunt SP. 2004. Mechanisms that generate and maintain bone cancer pain. Novartis Found Symp 260:221-238;
106. discussion 238-240,277-279.
107. Mao-Ying QL, Zhao J, Dong ZQ, Wang J, Yu J, Yan MF, Zhang YQ, Wu GC, Wang YQ. 2006. A rat model of bone cancer pain induced by intratibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun 345:1292-1298.
108. Martin LA, Hagen NA. 1997. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage 14:99-117.
109. Matsumoto M, Inoue M, Hald A, Xie W, Ueda H. 2006. Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J Pharmacol Exp Ther 318:735-740.
110. Mayer MN, Grier CK. 2006. Palliative radiation therapy for canine osteosarcoma. Can Vet J 47:707-709.
111. McDonald ES, Windebank AJ. 2002. Cisplatin-induced apoptosis of DRG neurons involves BAX redistribution and cytochrome C release but not FAS receptor signaling. Neurobiol Dis 9:220-233.
112. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O'Reilly T, Wotherspoon G, Winter J, Green J, Urban L. 2002. A rat model of bone cancer pain. Pain 96:129-140.
113. Menendez L, Lastra A, Fresno MF, Llames S, Meana A, Hidalgo A, Baamonde A. 2003. Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain. Brain Res 969:102-109.
114. Menendez L, Lastra A, Hidalgo A, Meana A, Garcia E, Baamonde A. 2003. Peripheral opioids act as analgesics in bone cancer pain in mice. Neuroreport 14:867-869.
115. Mercadante S. 1997. Malignant bone pain: pathophysiology and treatment. Pain 69:1-18.
116. Mercadante S, Arcuri E. 1998. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24:425-432.
117. Mercadante S, Fulf aro F. 2007. Management of painful bone metastases. Curr Opin Oncol 19:308-314.
118. Meunier A, Latremoliere A, Dominguez E, Mauborgne A, Philippe S, Hamon M, Mallet J, Benoliel JJ, Pohl M. 2007. Lentiviral-mediated targeted NF-κB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. Mol Ther 15:687-697.
119. Miguel R. 2000. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 7:149-156.
120. Mimura Y, Kato H, Eguchi K, Ogawa T. 2000. Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology 21:513-520.
121. Mishra S, Bhatnagar S, Singhal AK. 2004. Recent trends in cancer pain management. Indian J Med Paediatric Oncol 25:22-28.
122. Mogil JS, Crager SE. 2004. What should we be measuring in behavioral studies of chronic pain in animals? Pain 112:12-15.
123. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, Elmer GI, Chung JM, Devor M. 1999. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 80:67-82.
124. Mullins MN, Lana SE, Dernell WS, Ogilvie GK, Withrow SJ, Ehrhart EJ. 2004. Cyclooxygenase 2 expression in canine appendicular osteosarcomas. J Vet Intern Med 18:859-865.
125. Nagae M, Hiraga T, Yoneda T. 2007. Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 25:99-104.
126. Nagamine K, Ozaki N, Shinoda M, Asai H, Nishiguchi H, Mitsudo K, Tohnai I, Ueda M, Sugiura Y. 2006. Mechanical allodynia and thermal hyperalgesia induced by experimental squamous cell carcinoma of the lower gingiva in rats. J Pain 7:659-670.
127. Niiyama Y, Kawamata T, Yamamoto J, Omote K, Namiki A. 2007. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 148:560-572.
128. Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. 2001. Vincristine-induced allodynia in the rat. Pain 93:69-76.
129. Nutile-McMenemy N, Elfenbein A, Deleo JA. 2007. Minocycline decreases in vitro microglial motility, β1 integrin, and Kv1.3 channel expression. J Neurochem 103:2035-2046.
130. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N. 1995. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1:599-606.
131. Park HC, Seong J, An JH, Kim J, Kim UJ, Lee BW. 2005. Alteration of cancer pain-related signals by radiation: proteomic analysis in an animal model with cancer bone invasion. Int J Radiat Oncol Biol Phys 61:1523-1534.
132. Peters CM, Lindsay TH, Pomonis JD, Luger NM, Ghilardi JR, Sevcik MA, Mantyh PW. 2004. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 126:1043-1052.
133. Polomano RC, Bennett GJ. 2001. Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2:8-14.
134. Polomano RC, Mannes AJ, Clark US, Bennett GJ. 2001. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug paclitaxel. Pain 94:293-304.
135. Portenoy RK, Hagen NA. 1990. Breakthrough pain: definition, prevalence, and characteristics. Pain 41:273-281.
136. Portenoy RK, Lesage P. 1999. Management of cancer pain. Lancet 353:1695-1700.
137. Pradat PF, Kennel P, Naimi-Sadaoui S, Finiels F, Scherman D, Orsini C, Delaere P, Mallet J, Revah F. 2002. Viral and nonviral gene therapy partially prevents experimental cisplatin-induced neuropathy. Gene Ther 9:1333-1337.
138. Quasthoff S, Hartung HP. 2002. Chemotherapy-induced peripheral neuropathy. J Neurol 249:9-17.
139. Regan JM, Peng P. 2000. Neurophysiology of cancer pain. Cancer Control 7:111-119.
140. Rollin BE. 2003. Oncology and ethics. Reprod Domest Anim 38:50-53.
141. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. 1993. Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107-115.
142. Rowinsky EK, Donehower RC. 1993. The clinical pharmacology of paclitaxel (taxol). Semin Oncol 20:16-25.
143. Rowinsky EK, Donehower RC. 1995. Paclitaxel (taxol). N Engl J Med 332:1004-1014.
144. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. 1993. Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 20:1-15.
145. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, Peters CM, Rogers SD, Schwei MJ, de Felipe C, Mantyh PW. 2002. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase 2. Cancer Res 62:7343-7349.
146. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, Mantyh PW. 2003. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 104:550-558.
147. Sabino MA, Mantyh PW. 2005. Pathophysiology of bone cancer pain. J Support Oncol 3:15-24.
148. Sahenk Z, Barohn R, New P, Mendell JR. 1994. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51:726-729.
149. Saito O, Aoe T, Yamamoto T. 2005. Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and morphine in a mouse model of bone cancer pain. J Anesth 19:218-224.
150. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW. 1999. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19:10886-10897.
151. Seong J, Park HC, Kim J, Kim UJ, Lee BW. 2004. Radiation-induced alteration of pain-related signals in an animal model with bone invasion from cancer. Ann N Y Acad Sci 1030:179-186.
152. Sessle BJ. 2007. Glia: non-neural players in orofacial pain. J Orofac Pain 21:169-170.
153. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, Mantyh PW. 2005. AntiNGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115:128-141.
154. Sevcik MA, Jonas BM, Lindsay TH, Halvorson KG, Ghilardi JR, Kuskowski MA, Mukherjee P, Maggio JE, Mantyh PW. 2006. Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. Gastroenterology 131:900-910.
155. Shimoyama M, Tanaka K, Hasue F, Shimoyama N. 2002. A mouse model of neuropathic cancer pain. Pain 99:167-174.
156. Shimoyama M, Tatsuoka H, Ohtori S, Tanaka K, Shimoyama N. 2005. Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer pain. Pain 114:221-230.
157. Smith SB, Crager SE, Mogil JS. 2004. Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains. Life Sci 74:2593-2604.
158. Socinski MA, Langer CJ. 1999. Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. Semin Oncol 26:51-61, discussion 71-72.
159. Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, Reiners C, Mockel C, Seeber S, Scheulen ME. 2002. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for nonseminomatous testicular cancer. Ann Oncol 13:229-236.
160. Tamura T, Sasaki Y, Nishiwaki Y, Saijo N. 1995. Phase I study of paclitaxel by 3-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86:1203-1209.
161. Tanner KD, Levine JD, Topp KS. 1998. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 395:481-492.
162. Tanner KD, Reichling DB, Levine JD. 1998. Nociceptor hyperresponsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 18:6480-6491.
163. Tassler P, Dellon AL, Lesser GJ, Grossman S. 2000. Utility of decompressive surgery in the prophylaxis and treatment of cisplatin neuropathy in adult rats. J Reconstr Microsurg 16:457-463.
164. ter Laak MP, Hamers FP, Kirk CJ, Gispen WH. 2000. rhGGF2 protects against cisplatin-induced neuropathy in the rat. J Neurosci Res 60:237-244.
165. Thomas EM, Weiss SM. 2000. Nonpharmacological interventions with chronic cancer pain in adults. Cancer Control 7:157-164.
166. Thompson SW, Tonge D. 2000. Bone cancer gain without the pain. Nat Med 6:504-505.
167. Thrall DE, LaRue SM. 1995. Palliative radiation therapy. Semin Vet Med Surg (Small Arum) 10:205-208.
168. Topp KS, Tanner KD, Levine JD. 2000. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 424:563-576.
169. Tyner TR, Parks N, Faria S, Simons M, Stapp B, Curtis B, Sian K, Yamaguchi KT. 2007. Effects of collagen nerve guide on neuroma formation and neuropathic pain in a rat model. Am J Surg 193:el-e6.
170. Ueda H. 2006. Molecular mechanisms of neuropathic pain - phenotypic switch and initiation mechanisms. Pharmacol Ther 109:57-77.
171. Urch C. 2004. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 18:267-274.
172. Urch CE. 2004. Current and potential treatment for cancer-induced bone pain. Am Acad Hospice Palliative Med Bull 1-3:7.
173. Urch CE, Donovan-Rodriguez T, Dickenson AH. 2003. Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain 106:347-356.
174. Urch CE, Donovan-Rodriguez T, Gordon-Williams R, Bee LA, Dickenson AH. 2005. Efficacy of chronic morphine in a rat model of cancer-induced bone pain: behavior and in dorsal horn pathophysiology. J Pain 6:837-845.
175. Valeberg BT, Rustoen T, Bjordal K, Hanestad BR, Paul S, Miaskowski C. 2008. Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. Eur J Pain 12:582-590.
176. Vecht CJ. 2000. Cancer pain: a neurological perspective. Curr Opin Neurol 13:649-653.
177. Vermeirsch H, Nuydens RM, Salmon PL, Meert TF. 2004. Bone cancer pain model in mice: evaluation of pain behavior, bone destruction, and morphine sensitivity. Pharmacol Biochem Behav 79:243-251.
178. Vit JP, Ohara PT, Tien DA, Fike JR, Eikmeier L, Beitz A, Wilcox GL, Jasmin L. 2006. The analgesic effect of low-dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuromediators of nociception. Pain 120:188-201.
179. von Frey M. 1922. Verspätete schmerzempfindungen. Z Gesamte Neurol Psychiatr 79:324-333.
180. Wacnik PW, Baker CM, Herron MJ, Kren BT, Blazar BR, Wilcox GL, Hordinsky MK, Beitz AJ, Ericson ME. 2005. Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 115:95-106.
181. Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, Wilcox GL. 2001. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 21:9355-9366.
182. Wacnik PW, Eikmeier LJ, Simone DA, Wilcox GL, Beitz AJ. 2005. Nociceptive characteristics of tumor necrosis factor a in naive and tumor-bearing mice. Neuroscience 132:479-491.
183. Wacnik PW, Kehl LJ, Trempe TM, Ramnaraine ML, Beitz AJ, Wilcox GL. 2003. Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain 101:175-186.
184. Wacnik PW, Stool L, Lauretti GR, Kitto KF, Ramnaraine ML, Mantyh PW, Beitz AJ, Wilcox GL. 1998. A practical model of cancer pain: comparing different hindlimb sites of melanoma cell implantation. Soc Neurosci Abstr (Los Angeles, CA) 24:628.
185. Wacnik PW, Wilcox GL, Clohisy DR, Ramnaraine ML, Eikmeier LJ, Beitz AJ. 2000. Cancer pain mechanisms and animal models of cancer pain. Proc 9th World Congress Pain Progress Pain Res Manage 16:615-637.
186. Walker K, Medhurst SJ, Kidd BL, Glatt M, Bowes M, Patel S, Mc-Nair K, Kesingland A, Green J, Chan O, Fox AJ, Urban LA. 2002. Disease modifying and anti-nociceptive effects of the bisphosphonate zoledronic acid in a model of bone cancer pain. Pain 100:219-229.
187. Wang LX, Wang ZJ. 2003. Animal and cellular models of chronic pain. Adv Drug Deliv Rev 55:949-965.
188. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. 2007. Norman Cousins lecture. Glia as the bad guys:' implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 21:131-146.
189. Watkins LR, Milligan ED, Maier SF. 2001. Glial activation: a driving force for pathological pain. Trends Neurosci 24:450-455.
190. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. 1987. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5:1232-1239.
191. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. 1987. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486-2493.
192. Wood LJ, Nail LM, Gilster A, Winters KA, Elsea CR. 2006. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 33:535-542.
193. Yamamoto J, Kawamata T, Niiyama Y, Omote K, Namiki A. 2008. Downregulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 151:843-853.
194. Zhang RX, Liu B, Wang L, Ren K, Qiao JT, Berman BM, Lao L. 2005. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 118:125-136.
195. Zhou QL, Strichartz G, Davar G. 2001. Endothelin 1 activates ET(A) receptors to increase intracellular calcium in model sensory neurons. Neuroreport 12:3853-3857.
196. Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M, Buchler MW. 1999. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 17:2419-2428.
197. Zwolak P, Dudek AZ, Bodempudi VD, Nguyen J, Hebbel RP, Gallus NJ, Ericson ME, Goblirsch MJ, Clohisy DR. 2008. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer 122:681-688.